TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04832477

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stigma counseling for PrEP use
Description: This counseling consists of a single-session (45 minute) delivered by trained peer counselors. The primary aims and relevant content areas for counseling are: (1) Assessing and discussing factors known to be drivers of emotional barriers to accessing health care. This counseling aim has two main sub-components: (a) participants will be asked about their prior experiences with accessing health care and their concerns regarding future access, and (b) the counseling will focus on creating personal agency around needing to prioritize one's health. (2) Evaluating concerns around discussing PrEP with health care providers. The counseling combines motivational interviewing with medical decisional balance, which focuses on points to consider when evaluating PrEP. (3) Promoting resiliency beliefs and positive adaptation. For this objective the counselor works with the participant to establish PrEP use goals and problem-solving strategies.
Study: NCT06694753

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT06623721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Movement-evoked transcutaneous auricular Vagus nerve stimulation
Description: Intervention requires wearing of an inertial measurement unit (IMU) sensor on an affected upper limb together with a transcutaneous auricular Vagus nerve (taVNS) stimulator on an outer ear on the contralateral side.~Intervention involves IMU measurement-evoked initiation of taVNS during conventional neurorehabilitation therapy that is defined by the patient\&amp;#39;s doctor and therapist. Typically this is around 60 minutes/day of 50-300 repetitive upper limb movements targeting specific deficits such as flexor synergies and/or wrist, triceps or shoulder activation.~taVNS intensity is calibrated at the start of every neurorehabilitation session by the patient to the maximal comfortable level with instructions to avoid pain or any serious discomfort. Patient is always accompanied by a therapist trained in the use of taVNS and the device is easy to immediately remove should any discomfort occur.
Study: NCT05185440

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GIFTSS Training
Description: training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIFTSS Training
Description: training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIFTSS Training
Description: training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIFTSS Training
Description: training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Collaborative
Description: learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Collaborative
Description: learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Scripts
Description: scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Scripts
Description: scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention
Study: NCT05655546

Intervention type: OTHER
Group type: OTHER
Intervention: Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
Description: Participants will receive at home COVID-19 test for themselves and others in their household.
Study: NCT04315649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D movie viewing
Description: 3D movie viewing
Study: NCT05005156

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
Description: All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
Description: All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
Study: NCT05071781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticotropin-release hormone
Description: intravenous CRH (100 µg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticotropin-release hormone
Description: intravenous CRH (100 µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticotropin-release hormone
Description: a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticotropin-release hormone
Description: a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
Study: NCT06694753

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT06694051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: marking
Description: axis marking
Study: NCT06689800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Get REAL
Description: Family health communication tool
Study: NCT06695572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO
Study: NCT06689800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Get REAL
Description: Family health communication tool

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Get REAL
Description: Family health communication tool
Study: NCT06622889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain Intervention Program
Description: The intervention program aims to help older adults with subjective cognitive decline understand the aging process and adopt a positive attitude toward aging, highlighting age-related benefits. The sessions also provide emotion regulation techniques and stress-coping strategies to encourage proactive problem-solving and build confidence in handling challenges. By recalling positive life experiences, the program seeks to strengthen emotional connections, enhance the sense of belonging, and reconstruct a meaningful later life.
Study: NCT05031325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection with Purastat
Description: Purastat (peptidic gel) application
Study: NCT05041426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Participants who are CMV R+ will receive LET prophylaxis for 6 months, and participants who are CMV D+/R- will receive LET prophylaxis for 12 months. The duration of prophylaxis is per current standard of care. LET will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If LET is co-administered with cyclosporin A (CsA), the dosage of LET should be decreased to 240 mg once daily. All patients will be followed for 12 weeks after completion of LET for the occurrence of CMV infection or disease after prophylaxis. Participants on this protocol will receive acyclovir 400 mg orally BID for the duration of LET therapy for herpes simplex virus and varicella zoster virus prophylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Historical controls will have received CMV prophylaxis with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
Study: NCT06361238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection
Description: Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
Study: NCT06693531

Intervention type: DRUG
Intervention: dupilumab
Description: No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
Study: NCT06704295

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control ad with dark gray product with tobacco flavor name
Description: The e-cigarette ad with a dark gray product with a tobacco flavor name

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dark gray product with strawberry flavor name
Description: The e-cigarette ad with a dark gray product with a strawberry flavor name

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorful (strawberry color) product with strawberry flavor name
Description: The e-cigarette ad with a colorful (strawberry color) product with strawberry flavor name

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorful (strawberry color) product with strawberry flavor name and image
Description: The e-cigarette ad with colorful (strawberry color) product with strawberry flavor name and strawberry image

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorful (strawberry color) product with strawberry flavor features
Description: The e-cigarette advertisement with colorful (strawberry color) product with strawberry flavor name, strawberry image, and strawberry flavor sensation descriptor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorful (strawberry color) product with strawberry flavor features and choice claim
Description: The e-cigarette ad with colorful (strawberry color) product with strawberry flavor name, strawberry image, strawberry flavor sensation descriptor, and flavor choice claim
Study: NCT06709274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80mg daily, for EGFR-positive patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: 600mg BID, for ALK-rearranged patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Description: Toripalimab 240mg + Platinum-based chemotherapy (Q3W for 4 cycles), followed by Toripalimab maintenance therapy (240mg Q3W for one year), for EGFR/ALK wildtype patients
Study: NCT04680936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: low dose dextrose solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 15 % in Water
Description: high dose dextrose solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic sodium chloride solution
Description: isotonic saline solution
Study: NCT06031662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-Burst Stimulation
Description: Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting MT

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intermittent Theta-Burst Stimulation
Description: Magventure Active/Placebo B70 coil specifically designed for randomized clinical trials with TMS. This system uses electrodes placed on the scalp to provide stimulation mimicking the active treatment condition
Study: NCT06258811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel, cispatin, tislelizumab
Description: Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
Study: NCT05971290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure administered by face mask

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ambient air
Description: Air (fraction of inspired oxygen) at 14000 feet in elevation
Study: NCT04936451

Intervention type: DEVICE
Group type: OTHER
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours.
Study: NCT05650151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
Study: NCT06504355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training program incorporating video aerobic exercise, action video game and resistive action video game
Description: Participants in the experimental group participated in three 60-minute training sessions each week for 12 weeks. One of the session was group training. The other two session were individual training. In the group training session, the participants participate in the video aerobic exercise; in the individual sessions, the participants play action and resistive action video games: Fitness Boxing 2 and Adventure Ring-Fit. All participants in the experimental group wore a hear rate monitoring watch so that the researchers make sure that medium level of physical activities was achieved in each session.
Study: NCT06143527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT04936451

Intervention type: DEVICE
Group type: OTHER
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours.

Intervention type: DEVICE
Group type: OTHER
Intervention: TENS (transcutaneous electrical nerve stimulation) ECOMODYN
Description: TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode.
Study: NCT05035264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in neutral position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in neutral position
Study: NCT04936451

Intervention type: DEVICE
Group type: OTHER
Intervention: TENS (transcutaneous electrical nerve stimulation) ECOMODYN
Description: TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode.
Study: NCT06710106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic + hypocaloric diet
Description: Study participants will add prebiotic formula in a natural yogurt every day to be consumed within a hypocaloric diet.
Study: NCT05035264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion
Description: Laryngeal mask insertion in neutral position
Study: NCT06710106

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + hypocaloric diet
Description: Study participants will add placebo formula in a natural yogurt every day to be consumed within a hypocaloric diet.
Study: NCT06703190

Intervention type: BIOLOGICAL
Intervention: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated
Description: Non-interventional observed exposure of the receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation) ≥14 days before testing for SARS-CoV-2
Study: NCT06695975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational self-analysis
Description: Occupational self analysis program is delivered in group sessions, each session lasting 45 minutes, twice a week. Also Individual sessions are held throughout the program with each participant, with the intention of clarifying certain concepts and resolving specific difficulties that were occurring.The thematic modules worked are 5; occupation-health and difficulty, occupational balance, adaptation strategies to difficulties, social relationships and knowing other realities.~The methodological strategies used to structure the program were the Model of Human Occupation (MOHO) and the See-Judge-Act methodology
Study: NCT04898504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floxuridine
Description: A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver Transplantation
Description: Patients randomized to this arm will be given 2nd line chemotherapy (regimen given at the discression of the treating oncologist) followed by liver-Tx
Study: NCT01172249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate + chondroitin sulfate - MANTECORP
Description: 1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine sulfate + chondroitin sulfate - CONDROFLEX
Description: 1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
Study: NCT06694480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FID-022
Description: Advanced solid tumors
Study: NCT06695325

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c test
Description: Patients will be asked to have a HbA1c test in the clinic with a venous draw and then either fingerprick or upper arm draw. They will do the latter again at home.
Study: NCT06688890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical hand rub with the reference product; n-propanol 60%.
Description: Propanol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical hand rub with the product P1; Sorbectol for 1 min.
Description: Sorbectol hand rub for 1 min. The applied volume of product is sufficient to keep the hand moist for a total time of 1 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical hand rub with the product P2; Sorbectol for 3 min.
Description: Sorbectol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical hand rub with the product P3; Sorbectol for 5 min.
Description: Sorbectol hand rub for 5 min. The applied volume of product is sufficient to keep the hand moist for a total time of 5 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
Study: NCT06694532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Comparative study between Hyalgan and Hyorth injectable products in TMJ Disorders by arthrocentesis of 2 syringes device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Comparative study between Hyalgan and Hyorth injectable products in TMJ Disorders by arthrocentesis of 2 syringes device
Study: NCT06232837

Intervention type: DEVICE
Intervention: Direct laryngoscopy using Macintosh blade
Description: Patients in operative room requiring direct laryngoscopy for endotracheal intubation

Intervention type: DEVICE
Intervention: Direct laryngoscopy using Macintosh blade
Description: Patients in operative room requiring direct laryngoscopy for endotracheal intubation